Akeso, Inc. (HKG:9926)
124.10
+0.70 (0.57%)
At close: Dec 5, 2025
Akeso Revenue
Akeso had revenue of 1.41B CNY in the half year ending June 30, 2025, a decrease of -61.61%. This brings the company's revenue in the last twelve months to 2.51B, up 33.97% year-over-year. In the year 2024, Akeso had annual revenue of 2.12B, down -53.08%.
Revenue (ttm)
2.51B CNY
Revenue Growth
+33.97%
P/S Ratio
41.55
Revenue / Employee
827.26K CNY
Employees
3,035
Market Cap
114.31B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 38.69B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| WuXi Biologics | 21.98B |
| Sino Biopharmaceutical | 33.49B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
| Alibaba Health Information Technology | 36.09B |
Akeso News
- 15 days ago - Summit C-Suite Risks Success, Akeso Wins Either Way - Seeking Alpha
- 25 days ago - Akeso, Inc. (AKESF) Presents at 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) - Slideshow - Seeking Alpha
- 6 weeks ago - Akeso, Inc. (AKESF) Presents at ESMO Congress 2025 - Slideshow - Seeking Alpha
- 6 weeks ago - China’s Akeso gets share boost as data shows cancer drug’s benefits - South China Morning Post
- 2 months ago - Akeso's Ligufalimab Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia - Nasdaq
- 3 months ago - Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Benzinga
- 3 months ago - Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst - Benzinga
- 3 months ago - Akeso (9926.HK) Soars on Positive Lung Cancer Drug Trial Results - GuruFocus